Profile data is unavailable for this security.
About the company
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
- Revenue in USD (TTM)837.32m
- Net income in USD-2.11bn
- Incorporated2018
- Employees2.84k
- LocationTilray Brands Inc265 Talbot Street WestLEAMINGTON N8H 5L4CanadaCAN
- Phone+1 (519) 322-8800
- Fax+1 (416) 934-2141
- Websitehttps://www.tilray.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | 214.30m | 162.50m | 568.07m | 64.00 | 3.51 | 1.51 | 3.41 | 2.65 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Ironwood Pharmaceuticals, Inc. | 296.15m | 24.02m | 582.12m | 100.00 | 33.11 | -- | 22.48 | 1.97 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 628.40m | 162.00 | 5.61 | 5.34 | 5.43 | 2.23 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 688.11m | 136.00 | -- | 6.93 | -- | 82.08 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 781.74m | 304.00 | -- | -- | -- | 2.57 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 785.60m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Pacira Biosciences Inc | 726.41m | 7.03m | 861.62m | 829.00 | 135.47 | 1.26 | 8.78 | 1.19 | 0.1571 | 0.1571 | 16.19 | 16.86 | 0.5155 | 1.08 | 6.12 | 876,249.70 | 0.4991 | 0.0898 | 0.5891 | 0.1062 | 79.39 | 74.50 | 0.9683 | 0.221 | 3.28 | -- | 0.3494 | 0.00 | 3.63 | 11.07 | 107.07 | -45.44 | -16.51 | -- |
| Tilray Brands Inc | 837.32m | -2.11bn | 885.45m | 2.84k | -- | 0.5606 | -- | 1.06 | -22.10 | -22.10 | 8.27 | 13.56 | 0.2662 | 2.19 | 7.55 | 294,624.60 | -66.88 | -- | -72.47 | -- | 28.02 | -- | -251.21 | -- | 1.72 | -2.41 | 0.1605 | -- | 4.10 | -- | -792.62 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 175.11m | -221.25m | 903.03m | 371.00 | -- | -- | -- | 5.16 | -3.05 | -3.05 | 2.40 | -6.14 | 0.5494 | 5.18 | 3.00 | 471,994.60 | -69.41 | -77.19 | -105.43 | -94.72 | 87.09 | -- | -126.35 | -475.57 | 1.69 | -2.47 | 3.95 | -- | 216.93 | -- | 33.82 | -- | -26.11 | -- |
| Amphastar Pharmaceuticals Inc | 719.89m | 98.09m | 953.23m | 1.98k | 10.33 | 1.22 | 6.16 | 1.32 | 2.03 | 2.03 | 14.93 | 17.28 | 0.449 | 2.20 | 5.14 | 364,315.30 | 6.12 | 9.83 | 6.82 | 11.35 | 49.46 | 50.52 | 13.63 | 18.26 | 2.90 | 8.36 | 0.4362 | 0.00 | -1.65 | 15.53 | -38.51 | 133.84 | 1.87 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 960.24m | 97.00 | 33.68 | 4.13 | 30.98 | 11.95 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 998.86m | 394.00 | -- | -- | -- | 3.75 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Day One Biopharmaceuticals Inc | 158.18m | -107.32m | 1.07bn | 178.00 | -- | 2.42 | -- | 6.77 | -1.04 | -1.04 | 1.53 | 4.28 | 0.2901 | 3.57 | 7.79 | 888,662.90 | -19.68 | -32.37 | -22.44 | -35.43 | 89.12 | -- | -67.85 | -209.67 | 7.91 | -- | 0.00 | -- | 20.60 | -- | -12.38 | -- | 110.70 | -- |
Data as of Mar 02 2026. Currency figures normalised to Tilray Brands Inc's reporting currency: US Dollar USD
5.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tidal Investments LLCas of 31 Dec 2025 | 2.32m | 1.99% |
| UBS Securities LLCas of 31 Dec 2025 | 691.00k | 0.59% |
| Hillsdale Investment Management, Inc.as of 31 Dec 2025 | 536.00k | 0.46% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 412.60k | 0.35% |
| Graham Capital Management LPas of 31 Dec 2025 | 359.54k | 0.31% |
| Global X Investments Canada, Inc.as of 31 Jan 2026 | 342.53k | 0.29% |
| Global X Management Co. LLCas of 31 Dec 2025 | 340.69k | 0.29% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 339.85k | 0.29% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 326.09k | 0.28% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 309.89k | 0.27% |
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
